Study the Estradiol Add-on Benefit with Oral Ovarian Inducti | 59213

Journal of Research in Medical and Dental Science
eISSN No. 2347-2367 pISSN No. 2347-2545

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Study the Estradiol Add-on Benefit with Oral Ovarian Induction Medication in Subfertile Patients with PCOS or Unexplained Subfertility

Author(s): Median Atia Alkhalaf Almamou* and Asim Kurjak


Background: Estrogen might help when there is a decrease in estrogen quantity or increase in estrogen receptor antagonization. These effects occur when we use oral agents for ovulation induction. The use of estradiol add-on needs more research to assess its value in ovulation induction. Doppler studies might be beneficial in the management of subfertility. Methods: This study is a randomized prospective study. We recruited subfertile Patients with PCOS or unexplained subfertility from the infertility unit at Al-Moosa Specialist Hospital in eastern province in the Kingdom of Saudi Arabia. We randomized patients into four groups: clomiphene group, letrozole group, clomiphene with estrogen add-on group or letrozole with estrogen add-on group. We did a uterine and sub-endometrial doppler study on the hCG trigger day and on the mid-luteal phase day. We also studied endometrial thickness, pattern and vascularity zones. Results: When adding estradiol, there was a high cancellation rate for both clomiphene and letrozole groups (27.8%, 46.67% respectively) with a p-value of (0.007, 0.001 respectively). Conclusions: When using oral ovulation induction medications, it is not wise to add estradiol from day nine till ovulation day as it will be associated with a high cancellation rate.

Share this article